Podcast: What Does The Pfizer/Seagen Merger Mean For M&A In 2023?

Pfizer Inc.’s $43bn offer to buy Seagen Inc. in March was the biggest biopharmaceutical merger-and-acquisition deal since 2019. With 2022 having yielded the lowest amount of biopharma M&A by dollar value in several years, Scrip’s Joseph Haas discussed the Pfizer/Seagen deal, biopharma deal-making in 2022 and where it may be headed in 2023 with Mike King, managing director and head of healthcare research at EF Hutton Group, and Matt Gardella, an attorney focused on biopharma deal-making at US law firm Mintz.

The macro-economic environment continues to create challenging conditions, and the impacts of the Inflation Reduction Act of 2022 are just starting to be felt in the biopharma sector. King noted...